Skip to content

Comparison of the effect of methylprednisolone and dexamethasone in prime solution

Comparative study of clinical outcomes of methylprednisolone and dexamethasone in prime solution during cardiopulmonary pump after coronary artery bypass grafting in patients candidate for bypass surgery

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170620034666N2
Enrollment
62
Registered
2019-09-24
Start date
2019-07-31
Completion date
Unknown
Last updated
2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery bypass graft surgery. Mechanical complication of coronary artery bypass graft and biological heart valve graft

Interventions

Intervention 1: Intervention group 1: In dexamethasone group, 8 mg dexamethasone (Iran Hormone Company) is used in the prime solution. In the first 24 hours after surgery, the patient receives 8 mg de

Sponsors

Isfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: All patients undergoing coronary artery bypass grafting surgery Consent to participate in the study

Exclusion criteria

Exclusion criteria: History of valve surgery Less than 40 years old and over than 60 years old Ejection fraction less than 40%

Design outcomes

Primary

MeasureTime frame
Bleeding. Timepoint: After surgery. Method of measurement: Observation.;Hospitalization days. Timepoint: At the time of discharge. Method of measurement: Based on the day.;Inotrope intake. Timepoint: After the surgery. Method of measurement: Based on the recorded checklist.;Duration of mechanical ventialtion. Timepoint: At the time of discharge. Method of measurement: Based on the hour.;Arrhythmia. Timepoint: Continuously until discharge from cardiac intensive care unit. Method of measurement: Electrocardiogram.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehran Shahzamani

Esfahan University of Medical Sciences

m.shahzamani@med.mui.ac.ir+98 31 3670 1227

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 16, 2026